Dermatol. praxi. 2011;5(2):81-85

Quo Vadis in the antifungal treatment of gynecological problems at the beginning of the third millennium ?

doc.MUDr.Jiří ©paček, Ph.D.1, doc.RNDr.Vladimír Buchta, CSc.2,3, PharmDr.Petr Jílek, CSc.3, MUDr.Jan Kestřánek1, MUDr.Vojtěch Matula1
1 Klinika porodnictví a gynekologie, Fakultní nemocnice a LF UK v Hradci Králové
2 Ústav klinické mikrobiologie, Fakultní nemocnice a LF UK v Hradci Králové
3 Katedra biologických a lékařských věd, FaF UK v Hradci Králové

While acute episodes of vulvovaginal candidiasis is a highly efficient single antifungal therapy for chronic vulvovaginal discomfort

yeast origin tends to have only a temporary application of antifungal effect. In the long term, chronic conditions more favorable to influence

the quality of the vaginal environment, and there we have many resources. Vagina and external genitalia are strongly estrogen

areas and thus offers the possibility of hormonal interventions.

Keywords: vulvovaginal candidiasis, chronic vulvovaginal discomfort, Candida albicans, therapy

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©paček J, Buchta V, Jílek P, Kestřánek J, Matula V. Quo Vadis in the antifungal treatment of gynecological problems at the beginning of the third millennium ? Dermatol. praxi. 2011;5(2):81-85.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ©paček J, Jílek P, Buchta V, et al. Protihoubová imunita a její mechanismy ve vztahu k vulvovaginální kandidóze. Čs Gynek 2004; 69: 133-140.
    2. Buchta V, ©paček J, Jílek P. Mykotické infekce ľenského genitálu I. Epidemiologie a mikrobiologie. Gynekolog, 1997; 2: 67-70.
    3. Sobel JD, Vazquez J, Lynch M, et al. Vaginitis due to Saccharomyces cerevisiae - epidemiology, clinical aspects and therapy. Clin Infect Dis., 1993; 16: 93-99. Go to original source... Go to PubMed...
    4. ©paček J, Buchta V, Veselský Z, et al. Interakce kvasinek s hostitelem ve vztahu k urogenitálnímu traktu, vulvovaginální kandidóza, urologické aspekty mykotických onemocnění. Čs Gynek 2003; 68: 432-439.
    5. ©paček J, Buchta V. Itraconazole in the treatment of acute and recurrent vaginal candidosis: Comparison of the therapeutic effectiveness and occurrence of relapses in one-day and three-day regimens. Mycoses 2005; 48: 165-171. Go to original source... Go to PubMed...
    6. ©paček J, Buchta V, Jílek P, et al. What does it mean the diagnosis of recurrent vulvovaginal candidiasis? 9th World Congress for Infectious and Immunological Diseases in Obstetrics and Gynaecology, Urology and Dermatology, November 19-26, 2005, Maceio, Brazil, Book of Abstratcs, p. 62.
    7. ©paček J, Buchta V, Jílek P, et al. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Eur J Obst Gyn Repr Biol 2007; 131: 198-202. Go to original source... Go to PubMed...
    8. ©paček J, Buchta V, Jílek P, et al. Assessment of progesterone production in patients with recurrent vulvovaginal candidiasis. 9th World Congress for Infectious and Immunological Diseases in Obstetrics and Gynaecology, Urology and Dermatology, November 19-26, 2005, Maceio, Brazil, Book of Abstratcs, p. 65.
    9. Fidel PL, Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev 1996; 9: 335-348. Go to original source... Go to PubMed...
    10. Zdolsek B, Hellberg, D, Fröman G, et al. Vaginal microbiological flora and sexually transmitted diseases in women with recurrent vulvovaginal candidiasis. Infection 1995; 23: 81-84. Go to original source... Go to PubMed...
    11. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000; 61: 3306-3312, 3317.
    12. ©paček J, Jílek P, Buchta V, et al. Současné názory na etiopatogenezi rekurentní vulvovaginální kandidózy. Čs Gynek 1999; 64: 114-117.
    13. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 2004; 9: 876-883. Go to original source... Go to PubMed...
    14. ©paček J, Jílek P, Buchta V, et al. The levels of calcium, magnesium, iron and zinc in patients with recurrent vulvovaginal candidiasis during attack and remission and in healthy controls. Mycoses 2005; 48: 391-395. Go to original source... Go to PubMed...
    15. Giraldo P, Von Nowaskonski A, Gomes FAM, et al. Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. Obstet Gynecol 2000; 95: 413-416. Go to original source... Go to PubMed...
    16. Buchta V, ©paček J. Mikrobiologické nálezy u pacientek s rekurentní vulvovaginální kandidózou ve Fakultní nemocnici Hradec Králové v letech 1995-2002. Čs Gynek 2004; 69: 7-15.
    17. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol 2003; 189: 1297-1300. Go to original source... Go to PubMed...
    18. White DJ, Johnson EM, Warnock DW. Management of persistent vulvovaginal candidosis due to azole-resistant Candida glabrata. Genitourin. Med., 1993; 69: 112-114. Go to original source... Go to PubMed...
    19. Buchta V, Slezák R, ©paček J, Koą»álová M, Vejsová M, Doleľal M. Současné moľnosti léčby koľních a slizničních mykóz. Klin Farmakol Farm 2008; 22(2): 72-75.
    20. Buchta V, ©paček J, Jílek P. Mykotické infekce ľenského genitálu III. Terapie. Gynekolog 1998; 7: 73-82.
    21. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann N Y Acad Sci 1988; 544: 547-557. Go to original source... Go to PubMed...
    22. Redecha M, Korbel M, Niľňanská Z, et al. Vulvovaginální kandidóza. Gynekológia pre praxi 2007; 5: 117-123.
    23. Kestřánek J jr., Buchta V, ©paček J, et al. Problematika vulvovaginálního dyskomfortu z hlediska mezioborové spolupráce. EMI 2008; 57: 23-27.
    24. ©paček J, Buchta V, Jílek P, et al. Gestagens in the management of recurrent vulvovaginal candidiasis. J Chemother 2007; 19(Suppl 3): 101, 3rd Trends in Medical Mycology. 28-31 October 2007, Turin, Italy. Go to PubMed...
    25. Jílek P, ©paček J, Buchta V, et al. Systémová imunita u pacientek s rekurentní vulvovaginální kandidózou. Čs Gynek 2005; 70: 453-459.
    26. Clancy R, Corrigan E, Dunkley M, Eyers F. Recurrent vulvovaginal candidiasis - allergy or immune deficiency. Int Arch Allergy Immunol 1999; 118: 349-350. Go to original source... Go to PubMed...
    27. Fidel P, Jr. Immunity in vaginal candidiasis. Curr Opin Infect Dis 2005; 18: 107-111. Go to original source... Go to PubMed...
    28. Skřivánek A, Dvořák V, Hlaváčková O, et al. Wobenzym in the complex treatment of recurrent vulvovaginal candidiasis. 10th World Congress for Infectious and Immunological Diseases in Obstetrics and Gynaecology, Urology, Dermatology 2007. Proceedings (v tisku).
    29. Pidrman V. Deprese u ľen. In: Anders M, ed. Deprese z různých úhlů pohledu. Praha: Galén, 2006: 31-46.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.